Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab (2018)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.jacl.2018.03.088
- Subjects: DOENÇAS CARDIOVASCULARES; HIPERCOLESTEROLEMIA; COLESTEROL; DOENÇAS GENÉTICAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of clinical lipidology
- ISSN: 1933-2874
- Volume/Número/Paginação/Ano: v. 12, n. 4, p. 958-965, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
RIDKER, Paul M. et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. Journal of clinical lipidology, v. 12, n. 4, p. 958-965, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2018.03.088. Acesso em: 23 jan. 2026. -
APA
Ridker, P. M., Santos Filho, R. D. dos, Rose, L. M., Kastelein, J. J. P., Wei, C., Revkin, J., et al. (2018). Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. Journal of clinical lipidology, 12( 4), 958-965. doi:10.1016/j.jacl.2018.03.088 -
NLM
Ridker PM, Santos Filho RD dos, Rose LM, Kastelein JJP, Wei C, Revkin J, YUNIS C, Tardif J-C, Shear CL. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab [Internet]. Journal of clinical lipidology. 2018 ; 12( 4): 958-965.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.jacl.2018.03.088 -
Vancouver
Ridker PM, Santos Filho RD dos, Rose LM, Kastelein JJP, Wei C, Revkin J, YUNIS C, Tardif J-C, Shear CL. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab [Internet]. Journal of clinical lipidology. 2018 ; 12( 4): 958-965.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.jacl.2018.03.088 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
- Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia
- Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
- Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients
- Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
- Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications?
- Sodium intake and prevalence of hypertension in elementary school students
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary
Informações sobre o DOI: 10.1016/j.jacl.2018.03.088 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
